Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R. Postema
Cost-Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors as an Add-On to Metformin in the Treatment of Type 2 Diabetes Mellitus From a UK Healthcare System Perspective
BMC Health Services Research
Health Policy
Related publications
Dapagliflozin: Cost-Effectiveness as an Add-On Therapy to Metformin in the Treatment of Type 2 Diabetes (T2DM) in Argentina and Chile
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pdb81 - Dapagliflozin Is Cost-Effective Compared to DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Dapagliflozin (Forxiga®) Versus Glipizide as Add-On Therapies in Type 2 Diabetes Mellitus (T2dm); An Update of the Cost-Effectiveness Based on Long-Term Clinical Evidence From Uk NHS Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Linagliptin Versus Sulfonylurea as Add-On Treatment to Metformin for the Treatment of Diabetes Mellitus Type 2 Patients in Indonesia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-On Therapy to Metformin in Patients With Uncontrolled Type 2 Diabetes Mellitus
Diabetes Therapy
Internal Medicine
Endocrinology
Metabolism
Diabetes
Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
Prescription of DPP-4 Inhibitors to Type 2 Diabetes Mellitus Patients With Renal Impairment: A UK Primary Care Experience
Clinical Therapeutics
Pharmacology
Cost-Effectiveness of First-Line Versus Delayed Use of Combination Dapagliflozin and Metformin in Patients With Type 2 Diabetes
Scientific Reports
Multidisciplinary
